A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.